Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

CVS acknowledged that Zepbound has been shown to help people lose more weight than Wegovy, but that Wegovy can still help ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay programs at $499 monthly ...

The University of Pennsylvania is suing three leading insulin makers and companies that negotiate drug price deals for insurance plans, accusing them of a scheme to drive up prices of a medication ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

CVS Caremark estimates between 25 to 30 million people use ... Though the two drugs are both approved for weight loss, a study published in May funded by Eli Lilly found that patients on Zepbound were ...

Hims & Hers remains a compelling long-term play, with a resilient subscription-driven model, 85%+ retention, and 2.4 million ...

New Wegovy prescriptions have increased by about 33% since May 22, when a U.S. Food and Drug Administration ban on so-called ...

Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...